GeneDx Holdings (WGS) Income from Continuing Operations (2020 - 2026)
GeneDx Holdings (WGS) reported Income from Continuing Operations of 63316000.0 for Q1 2026, down 876.8% year-over-year from 8150903.88 in Q1 2025, and down 257.43% quarter-over-quarter from 17714000.0 in Q4 2025.
GeneDx Holdings (WGS) Income from Continuing Operations (2020 - 2026) Analysis & Trends
GeneDx Holdings (WGS) has 7 years of Income from Continuing Operations data on file, last reported at 63316000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 63316000.0, down 876.8% year-over-year; the trailing twelve-month figure through Mar 2026 was 77809000.0 (down 101.95% YoY), and the FY2025 annual result was 21021000.0, up 59.8% from the prior year.
- Income from Continuing Operations slipped to 63316000.0 in Q1 2026 per WGS's latest filing, from 17714000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 10809000.0 in Q2 2025 and troughed at 308719000.0 in Q4 2022.
- A 5-year average of 50662764.71 and a median of 29173000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations jumped 137.05% in 2025, then sank 876.8% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 308719000.0 in 2022, then surged by 91.66% to 25758000.0 in 2023, then soared by 121.11% to 5438000.0 in 2024, then slumped by 425.74% to 17714000.0 in 2025, then sank by 257.43% to 63316000.0 in 2026.
- Business Quant data shows WGS's Income from Continuing Operations at 63316000.0 in Q1 2026, 17714000.0 in Q4 2025, and 7588000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Waters | 29,902.70 Bn | 29,902.24 Bn | 1.11 Bn | -72.00 Mn |
| 2 | Thermo Fisher Scientific | 175.99 Bn | 172.74 Bn | 7.74 Bn | 1.66 Bn |
| 3 | Danaher | 129.87 Bn | 124.18 Bn | 3.59 Bn | 1.03 Bn |
| 4 | Idexx Laboratories | 44.75 Bn | 44.55 Bn | 722.74 Mn | 278.45 Mn |
| 5 | Agilent Technologies | 37.52 Bn | 35.72 Bn | 990.00 Mn | 339.00 Mn |
| 6 | Iqvia Holdings | 30.91 Bn | 28.94 Bn | 1.36 Bn | 269.00 Mn |
| 7 | Natera | 30.21 Bn | 29.11 Bn | 696.04 Mn | -85.11 Mn |
| 8 | Illumina | 24.19 Bn | 23.04 Bn | 721.00 Mn | 134.00 Mn |
| 9 | Mettler Toledo International | 23.12 Bn | 23.06 Bn | 555.82 Mn | 169.45 Mn |
| 10 | GeneDx Holdings | 1.52 Bn | 1.35 Bn | 68.21 Mn | -63.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.32 Mn |
| Dec 31, 2025 | -17.71 Mn |
| Sep 30, 2025 | -7.59 Mn |
| Jun 30, 2025 | 10.81 Mn |
| Mar 31, 2025 | -6.48 Mn |
| Dec 31, 2024 | 5.44 Mn |
| Sep 30, 2024 | -8.31 Mn |
| Jun 30, 2024 | -29.17 Mn |
| Mar 31, 2024 | -20.24 Mn |
| Dec 31, 2023 | -25.76 Mn |
| Sep 30, 2023 | -42.29 Mn |
| Jun 30, 2023 | -46.72 Mn |
| Mar 31, 2023 | -60.99 Mn |
| Dec 31, 2022 | -308.72 Mn |
| Sep 30, 2022 | -77.58 Mn |
| Jun 30, 2022 | -85.74 Mn |
| Mar 31, 2022 | -76.90 Mn |
| Dec 31, 2021 | -40.19 Mn |
| Sep 30, 2021 | 32.73 Mn |
| Jun 30, 2021 | -46.16 Mn |